First oral advanced therapy approved for moderate-to-severe Crohn’s disease
Upadacitinib has been approved for use in adults with moderate-to-severe Crohn's disease in the UK, marking the first marketing authorisation globally, and will now undergo appraisal by the National Institute for Health and Care Excellence.…
Published: 9 February 2023